Michael Mingueneau
Vice President & Head of Immunology Sail Bio
Seminars
Tuesday 21st July 2026
Programming T Cells In Vivo with Targeted Immune Nanoparticles Encapsulating eRNATM-Encoded hCD19 CAR for Transient Activation to Achieve Deep B-cell Depletion & Immune Reset
2:00 pm
- In vivo CAR-T cell engineering has the potential to transform the care of patients with autoimmune diseases by simplifying and broadening access to treatments with potential for cures
- Engineering an in vivo CAR-T drug candidate (DC) and extensively optimized to achieve an optimal dose efficiency profile and ultimately therapeutic index in patients with autoimmune conditions. As a result, in vivo CAR-T DC can achieve deep tissue depletion of B cells and effectively reset the B cell compartment at low dose levels
- In vivo CAR-T DC has the potential to replace complex, costly, and genome-integrative cell therapy products with an off-theshelf and non-integrative IV injectable product that avoids the safety risks associated with lymphoablative conditioning
